Annual report pursuant to Section 13 and 15(d)

Collaborative Arrangements - GSK Platform Technology Transfer, Collaboration and License Agreement (Details)

v3.20.4
Collaborative Arrangements - GSK Platform Technology Transfer, Collaboration and License Agreement (Details) - GSK Platform - USD ($)
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2014
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Liability, revenue recognized   $ 2,000,000.0    
Research and development revenue        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Liability, revenue recognized $ 0 $ 2,000,000.0 $ 0  
Minimum        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Contingent receivable       $ 5,750,000
Maximum        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Contingent receivable       $ 38,500,000